TITLE

Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

AUTHOR(S)
WAILOO, ALLAN; BANSBACK, NICK; CHILCOTT, JIM
PUB. DATE
February 2008
SOURCE
Rheumatology;Feb2008, Vol. 47 Issue 2, p119
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors explore evidence on the cost-effectiveness of infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis (AS). They note studies commissioned by Wyeth, Abbott and Schering Plough showing that tumor necrosis factor-α inhibitors are cost-effective than conventional therapy in the British National Health Service. They also mentioned the adoption of the Bath AS Functional Index (BASFI) and Bath AS Disease Activity Index (BASDAI) as modelling approaches in the analyses conducted.
ACCESSION #
44576685

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics